SCHEMBL3111198

SCHEMBL3111198

CCCC(=O)Nc1ccc(-n2nnc(C(=O)NC3CC3)c2CCC)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.49
▸ TP53 P04637 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ MAPT P10636 5/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.41
▸ GAA P10253 1/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC10 Q969S8 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3107068 0.93 ROCK1 (0.47) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3107465 0.93 ROCK1 (0.47) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3118319 0.92 ROCK1 (0.44) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3107194 0.91 ROCK1 (0.43) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3108746 0.91 ROCK1 (0.46) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3117945 0.91 ROCK1 (0.48) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3107060 0.91 ROCK1 (0.43) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3115248 0.91 ROCK1 (0.43) ROCK1TP53NPC1RAB9ASMN1; SMN2
SCHEMBL3099742 0.90 ROCK1 (0.48) ROCK1TP53SMN1; SMN2MAPTRXFP1
SCHEMBL3113422 0.89 ROCK1 (0.47) ROCK1RAB9AMAPTRXFP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 ROCK1 1430/4885TP53 2716/4885NPC1 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback